Related Experiment Videos

Oral combination therapy with thiazolidinediones in type 2 diabetes

James R LaSalle1, L Brian Cross

  • 1Medical Arts Research Collaborative, Excelsior Springs, Missouri, USA.

The American Journal of Managed Care
|November 23, 2006
PubMed

Insights

Early type 2 diabetes management with combination therapy, addressing insulin resistance and beta cell dysfunction, improves outcomes. Combining medications like sulfonylureas or metformin with thiazolidinediones is effective.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Insulin resistance is an early hallmark of type 2 diabetes, preceding overt disease and beta cell failure.
  • Macrovascular complications may be advanced at the time of diabetes diagnosis.
  • Monotherapy with sulfonylureas or metformin offers limited disease progression control.

Purpose of the Study:

  • To highlight the necessity of combination therapy for type 2 diabetes management.
  • To emphasize addressing both insulin resistance and beta cell dysfunction.
  • To support early, aggressive treatment strategies.

Main Methods:

  • Review of clinical trials supporting combination therapy.
  • Analysis of complementary mechanisms of action for diabetes medications.
  • Evaluation of treatment outcomes and healthcare costs.

Main Results:

  • Combination therapy targeting both insulin resistance and beta cell dysfunction is superior to monotherapy.
  • Agents with complementary mechanisms, such as sulfonylureas or metformin plus thiazolidinediones, show clinical trial support.
  • Early aggressive treatment strategies are associated with improved patient outcomes.

Conclusions:

  • Successful type 2 diabetes management requires combination therapy.
  • Early and aggressive treatment improves patient outcomes and reduces healthcare costs.
  • Combining agents with complementary actions is a key strategy for effective disease control.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...